TAVR in 2023: Who Should Not Get It?. [Review]
TAVR in 2023: Who Should Not Get It?. [Review]
- 2023
Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006
Since the first transcatheter delivery of an aortic valve prosthesis was performed by Cribier et al in 2002, the picture of aortic stenosis (AS) therapeutics has changed dramatically. Initiated from an indication of inoperable to high surgical risk, extending to intermediate and low risk, transcatheter aortic valve replacement (TAVR) is now an approved treatment for patients with severe, symptomatic AS across all the risk categories. The current evidence supports TAVR as a frontline therapy for treating severe AS. The crucial question remains concerning the subset of patients who still are not ideal candidates for TAVR because of certain inherent anatomic, nonmodifiable, and procedure-specific factors. Therefore, in this study, we focus on these scenarios and reasons for referring selected patients for surgical aortic valve replacement in 2023. Copyright © 2023 Elsevier Inc. All rights reserved.
English
0002-9149
10.1016/j.amjcard.2023.01.040 [doi] S0002-9149(23)00048-6 [pii]
*Aortic Valve Stenosis
*Heart Valve Prosthesis
*Heart Valve Prosthesis Implantation
*Transcatheter Aortic Valve Replacement
Aortic Valve Stenosis/et [Etiology]
Aortic Valve Stenosis/su [Surgery]
Aortic Valve/su [Surgery]
Heart Valve Prosthesis Implantation/ae [Adverse Effects]
Heart Valve Prosthesis/ae [Adverse Effects]
Humans
Risk Factors
Transcatheter Aortic Valve Replacement/ae [Adverse Effects]
Treatment Outcome--Automated
MedStar Heart & Vascular Institute
MedStar Washington Hospital Center
Advanced Cardiac Catheterization Research Fellowship
Interventional Cardiology Fellowship
Journal Article
Review
Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006
Since the first transcatheter delivery of an aortic valve prosthesis was performed by Cribier et al in 2002, the picture of aortic stenosis (AS) therapeutics has changed dramatically. Initiated from an indication of inoperable to high surgical risk, extending to intermediate and low risk, transcatheter aortic valve replacement (TAVR) is now an approved treatment for patients with severe, symptomatic AS across all the risk categories. The current evidence supports TAVR as a frontline therapy for treating severe AS. The crucial question remains concerning the subset of patients who still are not ideal candidates for TAVR because of certain inherent anatomic, nonmodifiable, and procedure-specific factors. Therefore, in this study, we focus on these scenarios and reasons for referring selected patients for surgical aortic valve replacement in 2023. Copyright © 2023 Elsevier Inc. All rights reserved.
English
0002-9149
10.1016/j.amjcard.2023.01.040 [doi] S0002-9149(23)00048-6 [pii]
*Aortic Valve Stenosis
*Heart Valve Prosthesis
*Heart Valve Prosthesis Implantation
*Transcatheter Aortic Valve Replacement
Aortic Valve Stenosis/et [Etiology]
Aortic Valve Stenosis/su [Surgery]
Aortic Valve/su [Surgery]
Heart Valve Prosthesis Implantation/ae [Adverse Effects]
Heart Valve Prosthesis/ae [Adverse Effects]
Humans
Risk Factors
Transcatheter Aortic Valve Replacement/ae [Adverse Effects]
Treatment Outcome--Automated
MedStar Heart & Vascular Institute
MedStar Washington Hospital Center
Advanced Cardiac Catheterization Research Fellowship
Interventional Cardiology Fellowship
Journal Article
Review